Oncocyte Corporation (OCX) Dividend History

Oncocyte Corporation (OCX) is a biotechnology company focused on the development and commercialization of diagnostic tests for cancer detection and treatment. It specializes in molecular diagnostic tools to assist clinicians in making more informed decisions, particularly in the areas of lung and breast cancer. The company's primary product is the DetermaIO, a gene expression test designed to assess the likelihood of cancer recurrence and guide treatment strategies.

15 Cushing, Irvine, CA, 92618
Phone: 949-409-7600
Website:

Dividend History

Oncocyte Corporation currently does not pay dividends

Company News

  • Oncocyte Signs Leading Transplant Centers in US and Germany

    Oncocyte Corporation announced that its GraftAssure research assay has been adopted by two leading transplant university hospitals in the U.S. and Germany. The company has also submitted a plan for an IVD version of its dd-cfDNA kitted test to the FDA, marking a critical step in the product development process.

    GlobeNewswire Inc.
  • Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

    Oncocyte Corporation announced a $10.2 million private placement of securities, with participation from new and existing investors, including strategic partner Bio-Rad Laboratories. The company plans to use the proceeds for working capital and general corporate purposes.

    GlobeNewswire Inc.
    Featured Companies: BIO BIO.B
  • Oncocyte Corp confirms board independence and ratifies accounting firm By Investing.com - Investing.com

    Oncocyte Corp held its 2024 Annual Meeting of Shareholders, resulting in the re-election of four directors and the ratification of its independent registered public accounting firm. The company also confirmed the independence of its board chairman.

    Investing.com
  • Oncocyte Appoints Andrea James as Chief Financial Officer

    Oncocyte Appoints Seasoned Finance Executive Andrea James as Chief Financial Officer

    GlobeNewswire Inc.
  • 4 Analysts Assess OncoCyte: What You Need To Know

    Analysts' ratings for OncoCyte (NASDAQ:OCX) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 1 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for OncoCyte, revealing an average target of $4.38, a high estimate of $5.00, and a low estimate of $4.00. This upward trend is evident, with the current average reflecting a 21.67% increase from the previous average price target of $3.60. Investigating Analyst Ratings: An Elaborate Study A comprehensive examination of how financial experts perceive OncoCyte is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Matson Needham Maintains Buy $4.25 - Mike Matson Needham Raises Buy $4.25 $3.60 Mason Carrico Stephens & Co. Maintains Equal-Weight $4.00 - Bruce Jackson Benchmark Maintains Speculative Buy $5.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related ...Full story available on Benzinga.com

    Benzinga
Dividend data last updated 06/07/2025 15:01:11 UTC